Health Economics›Follicular lymphoma›First-line therapy

First-line therapy

Follicular lymphoma · 19 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
FM Variant #01	—	R 17 425	21d	—	—	~6	~R 104 549 indirect	—
Cyclophosphamide and Fludarabine (FC) Variant #15	—	R 14 005	—	~20.6 mo	—	~8	~R 112 036 PFS proxy · indirect	3
Fludarabine, then 131Iodine-Tositumomab Variant #01 Partial	—	R 13 754	35d	—	—	~3	~R 41 262 indirect	—
Fludarabine monotherapy Variant #05	—	R 13 754	28d	~16.5 mo	~52.9 mo	~12	~R 165 047 PFS proxy · indirect	4
FND Variant #01	—	R 12 357	28d	—	—	~8	~R 98 858 indirect	—
MCP (Prednisolone) Variant #01	—	R 6 853	28d	—	—	~8	~R 54 823 indirect	—
MCP Variant #01	—	R 6 850	28d	—	—	~8	~R 54 799 indirect	—
CHOP-B Variant #01 Partial	—	R 2 086	21d	—	—	~6	~R 8 343 indirect	—
CHVP-I (Etoposide) Variant #01 Partial	—	R 1 722	56d	—	—	~6	~R 10 335 indirect	—
ProMACE-MOPP Variant #01 Partial	—	R 1 653	28d	—	—	~8	~R 13 226 indirect	—
CHOP, then 131Iodine-Tositumomab Variant #01 Partial	—	R 1 041	21d	—	—	~6	~R 6 249 indirect	—
COPA Variant #01	—	R 1 019	28d	—	—	~8	~R 8 156 indirect	—
CHVP-I (Prednisolone) Variant #01 Partial	—	R 902	60d	—	—	~6	~R 5 411 indirect	—
CHVP-I Variant #01 Partial	—	R 893	60d	—	—	~6	~R 5 355 indirect	—
CVP, then 131Iodine-Tositumomab Variant #01 Partial	—	R 863	21d	—	—	~6	~R 5 179 indirect	—
CHOP Variant #20	—	R 835	21d	~15.5 mo	—	~6	~R 5 011 PFS proxy · indirect	4
CVP Variant #01	—	R 613	21d	—	—	~8	~R 4 901 indirect	—
CHVP Variant #01 Partial	—	R 446	28d	—	—	~6	~R 2 678 indirect	—
131Iodine-Tositumomab monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—

19 of 19 regimens shown